Literature DB >> 16257097

Grey variants of the live vaccine strain of Francisella tularensis lack lipopolysaccharide O-antigen, show reduced ability to survive in macrophages and do not induce protective immunity in mice.

Gill Hartley1, Rosa Taylor, Jo Prior, Sarah Newstead, Paul G Hitchen, Howard R Morris, Anne Dell, Richard W Titball.   

Abstract

Francisella tularensis live vaccine strain (LVS) produces two colony types when grown on solid media, often referred to as blue variants (BV) and grey variants (GV). Whereas blue variant bacteria possessed a lipopolysaccharide O-side chain, grey variant bacteria lacked O-side chains. Grey variant bacteria appeared in stationary phase bacterial cultures and could be identified using a novel FACS-based assay. Compared to blue variant bacteria, grey variants showed a reduced ability to infect and survive in macrophages. The immunisation of mice with blue variant bacteria, but not grey variant bacteria, induced protective immunity towards fully virulent F. tularensis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16257097     DOI: 10.1016/j.vaccine.2005.08.075

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  28 in total

1.  Francisella tularensis Schu S4 O-antigen and capsule biosynthesis gene mutants induce early cell death in human macrophages.

Authors:  Stephen R Lindemann; Kaitian Peng; Matthew E Long; Jason R Hunt; Michael A Apicella; Denise M Monack; Lee-Ann H Allen; Bradley D Jones
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

2.  Role of the wbt locus of Francisella tularensis in lipopolysaccharide O-antigen biogenesis and pathogenicity.

Authors:  Catherine Raynaud; Karin L Meibom; Marie-Annick Lety; Iharilalao Dubail; Thomas Candela; Eric Frapy; Alain Charbit
Journal:  Infect Immun       Date:  2006-10-09       Impact factor: 3.441

3.  Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge.

Authors:  Leah E Cole; Barbara J Mann; Kari Ann Shirey; Katharina Richard; Yang Yang; Patricia J Gearhart; Kirsty L Chesko; Rose M Viscardi; Stefanie N Vogel
Journal:  J Leukoc Biol       Date:  2011-07-12       Impact factor: 4.962

4.  Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4.

Authors:  Karleigh A Hamblin; Stuart J Armstrong; Kay B Barnes; Carwyn Davies; Jonathan P Wong; James D Blanchard; Sarah V Harding; Andrew J H Simpson; Helen S Atkins
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

5.  Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.

Authors:  Katharina Richard; Barbara J Mann; Lenea Stocker; Eileen M Barry; Aiping Qin; Leah E Cole; Matthew T Hurley; Robert K Ernst; Suzanne M Michalek; Daniel C Stein; Philip Deshong; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

6.  Structure and function relations with a T-cell-activating polysaccharide antigen using circular dichroism.

Authors:  Lori S C Kreisman; Julia H Friedman; Andreea Neaga; Brian A Cobb
Journal:  Glycobiology       Date:  2006-09-21       Impact factor: 4.313

7.  The immunologically distinct O antigens from Francisella tularensis subspecies tularensis and Francisella novicida are both virulence determinants and protective antigens.

Authors:  Rebecca M Thomas; Richard W Titball; Petra C F Oyston; Kate Griffin; Emma Waters; Paul G Hitchen; Stephen L Michell; I Darren Grice; Jennifer C Wilson; Joann L Prior
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

Review 8.  Tularemia vaccines.

Authors:  Daniela Putzova; Iva Senitkova; Jiri Stulik
Journal:  Folia Microbiol (Praha)       Date:  2016-05-19       Impact factor: 2.099

Review 9.  Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development.

Authors:  Roger D Pechous; Travis R McCarthy; Thomas C Zahrt
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

Review 10.  Vaccines against tularemia.

Authors:  Eileen M Barry; Leah E Cole; Araceli E Santiago
Journal:  Hum Vaccin       Date:  2009-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.